Abstract: A packaging assembly can include a plurality of containers and a film. The packaging assembly can further include one or more tear lines disposed between adjacent containers, or between adjacent rows of containers. The tear lines can include scored tear lines or perforated tear lines. The scores or perforations can be formed by a laser, blade, or other implement. One or more containers can be removed from the packaging assembly by tearing the film along the tear line.

Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) such as TNF? muteins capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as a TNF? mutein, capable of specifically binding to a targeted immune system inhibitor such as soluble TNF receptor.

Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as an antibody, capable of specifically binding to the targeted immune system inhibitor.

Abstract: An ERCP catheter having a removable handle for a lithotriptor compatible basket is disclosed. The removable handle allows the catheter and handle assembly to be removed, leaving the basket in place within the duct and facilitates the use of a lithotriptor for mechanically crushing stone captured in the basket.

Abstract: An ERCP catheter having a removable handle for a lithotriptor compatible basket is disclosed. The removable handle allows the catheter and handle assembly to be removed, leaving the basket in place within the duct and facilitates the use of a lithotriptor for mechanically crushing stone captured in the basket.

Abstract: A multilayer film includes at least an abuse layer that is laser scored, and a sealant layer that has discrete weakened portions, due to the laser scoring. The multilayer film may have a tensile strength of between about 0.40 and 2.5 pounds per 10 millimeters at the location of the one or more weakened portions. In certain aspects, the tensile strength of the multilayer film is between about 7 and 14 pounds per inch at the location of the laser scoring on the abuse layer. Also, a package is provided that is formed from one or more multilayer films having a scored abuse layer and a sealant layer with weakened portions that allow steam and/or pressure to be vented from the package during heating. Optionally, the abuse layer includes a shallow scoring portion to provide an easy-open feature. For instance, the package may be used to cook frozen foods contained in the package, such as in a microwave oven.

Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) such as TNF? muteins capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as a TNF? mutein, capable of specifically binding to a targeted immune system inhibitor such as soluble TNF receptor.

Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as an antibody, capable of specifically binding to the targeted immune system inhibitor.

Abstract: A cover assembly for a vehicle carried open top container wherein a cover is connected at one end to a vertically adjustable tower and an opposite end to a cross member connected to a pair of pivot arms that are mounted at their lower ends to be pivoted by at least one hydraulic actuator that is mounted to the vehicle intermediate opposite ends of the container and adjacent the bottom thereof. An effective length of each pivot arm may be adjusted and locked in adjusted position.

Abstract: Provided is a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partners such as TNF? muteins capable of binding to and, thus, depleting the targeted immune system inhibitors from the biological fluids. Particularly useful is an adsorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as a TNF? mutein, capable of specifically binding to a targeted immune system inhibitor such as soluble TNF receptor.

Abstract: A cover assembly for a vehicle carried open top container wherein a cover is connected at one end to a vertically adjustable tower and an opposite end to a cross member connected to a pair of pivot arms that are mounted at their lower ends to be pivoted by at least one hydraulic actuator that is mounted to the vehicle intermediate opposite ends of the container and adjacent the bottom thereof. An effective length of each pivot arm may be adjusted and locked in adjusted position.

Abstract: A stent delivery system for positioning a first and second stent the first and second branch lumens of a bifurcation. The stent delivery system includes stent introducers and a sheath or catheter having a frangible wall. A method of delivering stents to anatomies such as bifurcated ducts or vessels.

Abstract: A training system uses a mechanical mock-up with electrically conductive probe points connected to electronically readable memories, and a simulated diagnostic tool to interface with a system or machine simulation for the purpose of operation, maintenance or procedure training. When a probe of a simulated diagnostic tool comes into contact with a probe point of the mechanical mock-up, the electronically readable memory supplies a unique identifier code that is communicated by the simulated diagnostic tool to the simulation to indicate the contact of the probe with the corresponding probe point. Complex wiring connections between the mechanical mock-up and a computer that runs the simulation are eliminated and construction of the training system is significantly simplified.

Abstract: An ERCP catheter having a removable handle for a lithotriptor compatible basket is disclosed. The removable handle allows the catheter and handle assembly to be removed, leaving the basket in place within the duct and facilitates the use of a lithotriptor for mechanically crushing stone captured in the basket.

Abstract: A medical apparatus assembly (10) comprises a medical device (11) that includes a side port assembly 13 adapted to combine a first pathway (37) for infusion of fluids with a second pathway (38) for wire guide (12) into a first passageway (26) while the second passageway (27) includes the third pathway (39), which comprises a control member (24), such as an electrical wire. The side port assembly is configured such that the first passageway communicates with both a first port (16), such as a fitting for connecting to a syringe, and a second port (15) which includes a sealing mechanism (32), such as a Tuohy-Borst fitting, thereby allowing the wire guide to be preloaded, instead of requiring it to be removed prior to infusing fluids. Optionally, a third port (43) may be included when external communication with the second passageway, is desired, such as balloons or baskets.

Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as an antibody, capable of specifically binding to the targeted immune system inhibitor.

Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as an antibody, capable of specifically binding to the targeted immune system inhibitor.

Abstract: Disclosed is a medical apparatus assembly (10) comprising a medical device (11) that includes a side port assembly 13 adapted to combine a first pathway (37) for infusion of fluids with a second pathway (38) for wire guide (12) into a first passageway (26) while the second passageway (27) includes the third pathway (39), which comprises a control member (24), such as an electrical wire. The side port assembly is configured such that the first passageway communicates with both a first port (16), such as a fitting for connecting to a syringe, and a second port (15) which includes a sealing mechanism (32), such as a Tuohy-Borst fitting, thereby allowing the wire guide to be preloaded, instead of requiring it to be removed prior to infusing fluids. Optionally, a third port (43) may be included when external communication with the second passageway, is desired, such as balloons or baskets.